No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AGEN240719C17000
- 1.40
- +0.65+86.67%
15min DelayClose Jun 28 15:57 ET
1.50High0.90Low
0.90Open0.75Pre Close58 Volume31 Open Interest17.00Strike Price5.60KTurnover117.15%IV9.85%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry1.40Extrinsic Value100Contract SizeAmericanOptions Type0.5367Delta0.0871Gamma9.71Leverage Ratio-0.0476Theta0.0039Rho5.21Eff Leverage0.0155Vega
Intraday
- 5D
- Daily
News
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)
Express News | Agenus Announces Extended BOT/BAL Therapy Yields Pronounced Tumor Reductions In Colon Cancer; Results From Investigator-Sponsored Trial Presented At 2024 ESMO Gastrointestinal Cancers Congress
Agenus Says Cancer Therapy Evaluation Program Is Accepting LOIs To Conduct Clinical Studies Using Botensilimab, Which Is Being Developed By CTEP As An Anticancer Agent In Collaboration With Company
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters
Express News | Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics
Agenus: Buell's Appointment Effective Immediately >AGEN
Agenus: Buell's Appointment Effective Immediately >AGEN
Comments
So $Agenus(AGEN.US$ owner bought shares at some low price at 0.6, then the price went down to 0.3 then reverse split.
Now the price is $15.00. Sometimes things get worse before it get better.
You could be a day trader and make your profit or cut losses or an investor and hold on.
I see some possibilities in this company and reverse split is to consolidate compliance. Now the ethics of the management or if they consider investor or shareholder investment is another d...
Now the price is $15.00. Sometimes things get worse before it get better.
You could be a day trader and make your profit or cut losses or an investor and hold on.
I see some possibilities in this company and reverse split is to consolidate compliance. Now the ethics of the management or if they consider investor or shareholder investment is another d...
2
$Agenus(AGEN.US$ Reuters· 5 mins ago
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
$Agenus(AGEN.US$ I knew the momentum wouldn't last.
Read more